vs
Side-by-side financial comparison of SOLENO THERAPEUTICS INC (SLNO) and Waldencast plc (WALD). Click either name above to swap in a different company.
Waldencast plc is the larger business by last-quarter revenue ($108.8M vs $66.0M, roughly 1.6× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -55.7%, a 95.1% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $-13.9M).
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
Waldencast plc is a global multi-brand platform focused on acquiring, developing and scaling high-growth premium niche brands across the beauty, personal care and wellness sectors. It operates primarily across North America and European markets, with core offerings including clean skincare, haircare, color cosmetics and wellness products targeted at quality-focused consumers.
SLNO vs WALD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $66.0M | $108.8M |
| Net Profit | $26.0M | $-60.6M |
| Gross Margin | 98.3% | 67.5% |
| Operating Margin | 33.5% | -42.9% |
| Net Margin | 39.4% | -55.7% |
| Revenue YoY | — | 17.8% |
| Net Profit YoY | 134.0% | — |
| EPS (diluted) | $0.47 | $-0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $66.0M | — | ||
| Q2 25 | $32.7M | — | ||
| Q4 23 | — | $108.8M | ||
| Q2 23 | — | $109.3M | ||
| Q4 22 | — | $92.4M |
| Q3 25 | $26.0M | — | ||
| Q2 25 | $-4.7M | — | ||
| Q4 23 | — | $-60.6M | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | 98.3% | — | ||
| Q2 25 | 97.9% | — | ||
| Q4 23 | — | 67.5% | ||
| Q2 23 | — | 62.4% | ||
| Q4 22 | — | 34.3% |
| Q3 25 | 33.5% | — | ||
| Q2 25 | -20.0% | — | ||
| Q4 23 | — | -42.9% | ||
| Q2 23 | — | -37.8% | ||
| Q4 22 | — | -136.8% |
| Q3 25 | 39.4% | — | ||
| Q2 25 | -14.4% | — | ||
| Q4 23 | — | -55.7% | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | $0.47 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q4 23 | — | $-0.65 | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $498.9M | $21.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $494.8M | $624.6M |
| Total Assets | $599.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $498.9M | — | ||
| Q2 25 | $286.8M | — | ||
| Q4 23 | — | $21.1M | ||
| Q2 23 | — | — | ||
| Q4 22 | — | $8.7M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | $179.3M |
| Q3 25 | $494.8M | — | ||
| Q2 25 | $240.1M | — | ||
| Q4 23 | — | $624.6M | ||
| Q2 23 | — | $767.3M | ||
| Q4 22 | — | $639.2M |
| Q3 25 | $599.9M | — | ||
| Q2 25 | $332.3M | — | ||
| Q4 23 | — | $1.0B | ||
| Q2 23 | — | — | ||
| Q4 22 | — | $1.1B |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.5M | $-13.4M |
| Free Cash FlowOCF − Capex | $43.5M | $-13.9M |
| FCF MarginFCF / Revenue | 65.8% | -12.7% |
| Capex IntensityCapex / Revenue | 0.0% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $43.5M | — | ||
| Q2 25 | $-12.6M | — | ||
| Q4 23 | — | $-13.4M | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | $43.5M | — | ||
| Q2 25 | $-12.6M | — | ||
| Q4 23 | — | $-13.9M | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | 65.8% | — | ||
| Q2 25 | -38.6% | — | ||
| Q4 23 | — | -12.7% | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q4 23 | — | 0.4% | ||
| Q2 23 | — | 1.0% | ||
| Q4 22 | — | 1.5% |
| Q3 25 | 1.67× | — | ||
| Q2 25 | — | — | ||
| Q4 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
